New Delhi, Feb. 17 -- Robert F. Kennedy Jr., the new Secretary of Health and Human Services, will now assess the use of selective serotonin reuptake inhibitors (SSRIs) as part of his early agenda in President Donald Trump's administration.

Kennedy Jr. is set to conduct a thorough investigation into the prevalence and potential dangers of commonly prescribed mental health and weight-loss medications. This assessment will focus on selective serotonin reuptake inhibitors (SSRIs), antipsychotics, antidepressants, mood stabilizers, stimulants, and weight-loss drugs, aiming to uncover any risks associated with their widespread use.

In a statement released by the White House on February 13, titled "Establishing The President's Make America Hea...